Malignant ascites enhance γδ T cell cytotoxicity toward ovarian cancer via chemokine-mediated recruitment

References

1. 1.↵
   2. Shen SP,
   3. Wang GR,
   4. Zhang RY,
   5. Zhao Y,
   6. Yu H,
   7. Wei YY, et al.

   Development and validation of an immune gene-set based Prognostic signature in ovarian cancer. Ebiomedicine. 2019; 40: 318–26.

   OpenUrlPubMed
2. 2.↵
   2. Asem M,
   3. Young A,
   4. Oyama C,
   5. ClaureDeLaZerda A,
   6. Liu YY,
   7. Ravosa MJ, et al.

   Ascites-induced compression alters the peritoneal microenvironment and promotes metastatic success in ovarian cancer. Sci Rep. 2020; 10: 11913.
3. 3.↵
   2. Ford CE,
   3. Werner B,
   4. Hacker NF,
   5. Warton K.

   The untapped potential of ascites in ovarian cancer research and treatment. Brit J Cancer. 2020; 123: 9–16.

   OpenUrlCrossRefPubMed
4. 4.↵
   2. Hu Y,
   3. Hu QL,
   4. Li YS,
   5. Lu LG,
   6. Xiang Z,
   7. Yin ZN, et al.

   γδ T cells: origin and fate, subsets, diseases and immunotherapy. Signal Transduct Target Ther. 2023; 8: 434.

   OpenUrlCrossRefPubMed
5. 5.↵
   2. Yuan LJ,
   3. Ma XQ,
   4. Yang YY,
   5. Qu YY,
   6. Li X,
   7. Zhu XY, et al.

   Phosphoantigens glue butyrophilin 3A1 and 2A1 to activate Vγ9Vδ2 T cells. Nature. 2023; 621: 840–8.

   OpenUrlCrossRefPubMed
6. 6.↵
   2. Kipps E,
   3. Tan DSP,
   4. Kaye SB.

   Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer. 2013; 13: 273–82.

   OpenUrlCrossRefPubMed
7. 7.↵
   2. Shender VO,
   3. Pavlyukov MS,
   4. Ziganshin RH,
   5. Arapidi GP,
   6. Kovalchuk SI,
   7. Anikanov NA, et al.

   Proteome-metabolome profiling of ovarian cancer ascites reveals novel components involved in intercellular communication. Mol Cell Proteomics. 2014; 13: 3558–71.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   2. Mempel TR,
   3. Lill JK,
   4. Altenburger LM.

   How chemokines organize the tumour microenvironment. Nat Rev Cancer. 2024; 24: 28–50.

   OpenUrlCrossRefPubMed
9. 9.↵
   2. Nagarsheth N,
   3. Wicha MS,
   4. Zou WP.

   Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017; 17: 559–72.

   OpenUrlCrossRefPubMed
10. 10.↵
    2. Gonsiorek W,
    3. Fan XD,
    4. Hesk D,
    5. Fossetta J,
    6. Qiu HC,
    7. Jakway J, et al.

    Pharmacological characterization of sch527123, a potent allosteric CXCR1/CXCR2 antagonist. J Pharmacol Exp Ther. 2007; 322: 477–85.

    OpenUrlAbstract/FREE Full Text